This is consistent with our current finding that the administration of anti-DJ-1 antibody decreased the expression of IL-23 in infiltrating immune cells on day 1 after stroke onset, leading to the suppression of TNFα and IL-1β expression in ischemic brain tissue on day 3 after stroke onset and to neuroprotection against ischemic brain injury. Here, IL23A is linked to stroke disorder.